Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection

Federal University of São Paulo

Status: Unknown

Conditions: Disorder of Transplanted Kidney; Cytomegalovirus Infections

Study type: Observational

Funder types: Other

Identifiers

NCT01353053

056410

Details and patient eligibility

About

The aim of this the study is to the assess whether the graft and patient survival, rejection rates and renal graft function after the first year will not differ between both study arms. The investigators will also the evaluate the reduction in the incidence of cytomegalovirus the and improvement of renal function of the everolimus after 1 year.

Enrollment: 82 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with BMI below 30,
• first transplants with PRA < 30,
• no contraindication for induction Thymoglobuline,
• age 18 years or younger than 70 years.

Exclusion criteria

• patients with a BMI above 30
• retransplantation
• patients hypersensitized with PRA > 30
• compared with Thymoglobulina indication for induction
• age under 18 or over 70 years

Trial design

82 participants in 1 patient group

Tacrolimus, Everolimus

Description:

Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.